abstract |
Provided are methods for reducing the risk of occurrence and/or the severity of pathogenic diseases (e.g., diseases associate with varicella zoster virus reactivation, influenza infection, and/or S. pneumoniae infection) in a subject that is receiving a gene therapy and an accompanying immunosuppressant regimen. |